

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: SCHNEIDER et al.  
Title: USE OF TWEAK MODULATORS AND INHIBITORS FOR THE  
TREATMENT OF NEUROLOGICAL CONDITIONS  
Appl. No.: 10/589823  
371(c) Date: 05/15/2007  
Examiner: Jennifer S. PITRAK  
Art Unit: 1635  
Confirmation Number: 2434

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 C.F.R. §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 C.F.R. §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 C.F.R. §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 C.F.R. §1.97(c), before the mailing date of either a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application.

Documents D1-D3 relate to a foreign proceeding involving related European Application No. 04004094.1.

Applicant requests that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

**FEE**

A fee in the amount of \$180.00 in accordance with 37 C.F.R. §1.17(p) to cover the fee associated with an information disclosure statement under 37 C.F.R. §1.97(c) is being paid by credit card via EFS-Web.

The Commissioner is hereby authorized to charge any additional fee which may be required regarding this request under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment instructions in EFS-Web being incorrect or absent, resulting in a rejected or incorrect credit card transaction, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 1 May 2009

By Brian McCaslin

FOLEY & LARDNER LLP  
111 Huntington Avenue  
Boston, Massachusetts 02199  
Telephone: (617) 342-4039  
Facsimile: (617) 342-4001

R. Brian McCaslin  
Attorney for Applicant  
Registration No. 48,571